Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients

Table 2

Patients with suppressed HBV VL 12 months after starting TDF/FTC.

	Detectable	Suppressed	𝑃=.067
3TC naïve (𝑛=10)	4 (40%)	6 (60%)	10 (100%)
3TC experienced (𝑛=14)	11 (79%)	3 (21%)	14 (100%)
Total	15	9	24